<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4866">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197898</url>
  </required_header>
  <id_info>
    <org_study_id>017-101-09-029</org_study_id>
    <nct_id>NCT01197898</nct_id>
  </id_info>
  <brief_title>Wound Edge Changes Following Treatment With Santyl</brief_title>
  <official_title>Evaluation of the Edge of Non-Healing Cutaneous Ulcers Following Debridement With Collagenase Santyl Ointment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate changes in the healing tissue of diabetic foot wounds
      following 14 days of treatment with Santyl or its vehicle base.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Extent of Presence/Absence of Epithelial Tongue.</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The results were found to be inconclusive due to the small number of biopsy specimens of sufficient quality for analysis. Four of the 10 subjects enrolled were not evaluable due to poor biopsy quality.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <condition>Diabetic Foot Wounds</condition>
  <arm_group>
    <arm_group_label>Collagenase Santyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ointment applied once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Base</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Applied once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collagenase Santyl Ointment</intervention_name>
    <description>Topical daily application</description>
    <arm_group_label>Collagenase Santyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Topical daily application</description>
    <arm_group_label>Vehicle Base</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for the study, subjects must meet the following inclusion criteria:

          -  Subjects should be presenting for the first time with a complaint of a non-healing
             wound, or may have failed one or more prior inadequate therapies. To improve
             homogeneity in the group studied, subjects with large wounds, complicated wounds,
             wounds of long duration, or who have failed multiple attempts at healing in which
             additional known critical variables were addressed (debridement, off loading, wound
             moisture control, wound infection control, blood glucose control, and/or adequate
             local blood supply) will be excluded.

          -  Provide written informed consent.

          -  Subjects 18 years of age or older, of either sex and of any race, with an existing
             diagnosis of Type I or Type II Diabetes Mellitus.

          -  Presenting for the first time with a complaint of a non-healing wound, or may have
             failed one or more prior inadequate therapies but not including therapies generally
             reserved for chronic wounds (i.e., debridement, off loading, wound moisture control,
             wound infection control, blood glucose control, and/or adequate local blood supply).

          -  Willing to attend all required study visits, and in the opinion of the Investigator,
             able to properly follow instructions regarding daily dressing changes (dressing
             changes may be done by a third party, who must agree to perform these daily).

          -  Body Mass Index less than or equal to 40

          -  A foot wound which meets the following criteria:

               -  Time since initial skin breakdown 56 - 112 days

               -  Wagner† Grade 1

               -  Area between 0.75 and 3.0 cm2, inclusive

               -  Located on plantar surface of midfoot or forefoot, dorsum of foot, or a
                  post-amputation wound

               -  Non-infected based on clinical assessment

          -  Adequate blood supply to the affected foot, defined as meeting a transcutaneous
             oxygen pressure(TcPO2) measured using standard technique and within 4 cm of the wound
             of greater than or equal to 35 mmHg.

          -  Blood chemistry and hematology values as follows, using local lab normal ranges
             unless otherwise specified:

               -  Blood Glycated Hemoglobin (HbA1C) 6.5 - 10.5%

               -  Blood Glucose less than or equal to 180 mg/dL

               -  Blood Hemoglobin, Hematocrit, Red Blood Cell count within normal limits

               -  Serum Sodium, Potassium, Calcium, Phosphorus, Carbon Dioxide (CO2) within normal
                  limits

               -  Serum Albumin greater than or equal to 2.0 g/dL, serum Pre-Albumin greater than
                  or equal to 15 mg/dL

               -  Alanine Transaminase (ALT), Aspartate Transaminase (AST), Gamma Glutamyl
                  Transpeptidase (GGT) less than or equal to 2.0 x Upper Limit of Normal (ULN)

               -  Blood Urea Nitrogen, Total Bilirubin, Creatinine less than or equal to 1.5 x ULN

          -  Wound is able to be off-loaded, if indicated. † Wagner Grade 1 = Superficial ulcer,
             partial or full-thickness, but not involving underlying fat, fascia, tendon, muscle
             or bone.

        Exclusion Criteria:

        Subjects meeting any of the following criteria during the screening period will be
        excluded from the study:

          -  Contraindications or hypersensitivity to the use of the study medications or their
             components

          -  Therapy with another investigational agent within thirty (30) days of Visit 1.

          -  Calluses or maceration of periwound area which would interfere with successful biopsy
             of the wound edge.

          -  Undermining or tunneling of the target wound.

          -  Evidence of osteomyelitis on screening roentgenogram of the target foot.

          -  Coagulation defect or bleeding disorder which, in the opinion of the Investigator,
             will make the biopsy procedures too risky.

          -  The Medical Monitor may declare any subject ineligible for a valid medical reason.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert B Slade, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Healthpoint</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Art J Tallis, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associated Foot &amp; Ankle Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associated Foot and Ankle Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>August 26, 2010</firstreceived_date>
  <firstreceived_results_date>March 13, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>Foot</keyword>
  <keyword>Ulcers</keyword>
  <keyword>Wounds</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with Type I or II diabetes mellitus and a non-healing foot ulcer including postamputation wounds and wounds on the dorsum of the foot.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Collagenase Santyl Ointment</title>
          <description>Applied once daily
Collagenase Santyl Ointment : Topical daily application</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Base</title>
          <description>Applied once daily
Placebo Comparator : Topical daily application</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Collagenase Santyl Ointment</title>
          <description>Applied once daily
Collagenase Santyl Ointment : Topical daily application</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Base</title>
          <description>Applied once daily
Placebo Comparator : Topical daily application</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="72.4" spread="8.3"/>
                <measurement group_id="B2" value="50.6" spread="10.2"/>
                <measurement group_id="B3" value="61.5" spread="14.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Extent of Presence/Absence of Epithelial Tongue.</title>
        <description>The results were found to be inconclusive due to the small number of biopsy specimens of sufficient quality for analysis. Four of the 10 subjects enrolled were not evaluable due to poor biopsy quality.</description>
        <time_frame>28 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Goal was to complete 10 subjects in an allocation ratio of 1:1 for Santyl vs. placebo. Since this was an exploratory study, the sample size was arbitrary.</population>
        <group_list>
          <group group_id="O1">
            <title>Collagenase Santyl Ointment</title>
            <description>Applied once daily
Collagenase Santyl Ointment : Topical daily application</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Base</title>
            <description>Applied once daily
Placebo Comparator : Topical daily application</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Extent of Presence/Absence of Epithelial Tongue.</title>
            <description>The results were found to be inconclusive due to the small number of biopsy specimens of sufficient quality for analysis. Four of the 10 subjects enrolled were not evaluable due to poor biopsy quality.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">The results were found to be inconclusive due to the small number of biopsy specimens of sufficient quality for analysis.</measurement>
                  <measurement group_id="O2" value="NA">The results were found to be inconclusive due to the small number of biopsy specimens of sufficient quality for analysis.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Collagenase Santyl Ointment</title>
          <description>Applied once daily
Collagenase Santyl Ointment : Topical daily application</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Base</title>
          <description>Applied once daily
Placebo Comparator : Topical daily application</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Cholecystitis</sub_title>
                <description>SAE judged to be not related to test article by the Investigator</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaime E. Dickerson, PhD; Sr. Director Clinical Affairs</name_or_title>
      <organization>Healthpoint, Ltd.</organization>
      <phone>817-302-3914</phone>
      <email>jaime.dickerson@healthpoint.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
